AIM in Phase 2 Study Evaluating Ampligen® for Treatment of Post-COVID Conditions

 Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions

Enrollment expected to be completed in Q4 2023

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced it has enrolled and dosed the first subject in the company’s Phase 2 study evaluating Ampligen^® as a potential therapeutic for people with post-COVID conditions (“AMP-518”). This important study milestone follows on the heels of the company having recently opened multiple clinical study sites and having screened numerous subjects. Study screening is ongoing and AIM expects to dose additional new subjects in the coming weeks. For more information about AMP-518, please visit ClinicalTrials.gov and reference identifier NCT05592418.

https://www.biospace.com/article/releases/aim-immunotech-enrolls-and-doses-first-subject-in-phase-2-study-evaluating-ampligen-for-the-treatment-of-post-covid-conditions/